KRAS mutation: The booster of pancreatic ductal adenocarcinoma transformation and progression

被引：34

作者：

Zhang, Zining ^{[1
,2
]}

Zhang, Heng ^{[1
,2
]}

Liao, Xiang ^{[1
,2
]}

Tsai, Hsiang-i ^{[1
,2
]}

机构：

[1] Jiangsu Univ, Inst Med Imaging & Artificial Intelligence, Zhenjiang, Peoples R China

[2] Jiangsu Univ, Affiliated Hosp, Dept Med Imaging, Zhenjiang, Peoples R China

来源：

FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY | 2023年 / 11卷

基金：

中国国家自然科学基金;

关键词：

PDAC; KRAS mutation; phosphokinase; metabolic reprogramming; therapy resistance; poorer prognosis; MUTANT KRAS; GLUTAMINE-METABOLISM; MOUSE MODEL; CANCER; CELL; INHIBITOR; INITIATION; GLYCOLYSIS; KRAS(G12D); EFFICACY;

D O I：

10.3389/fcell.2023.1147676

中图分类号：

Q2 [细胞生物学];

学科分类号：

071009 ; 090102 ;

摘要：

Pancreatic ductal adenocarcinoma (PDAC) is the most common type of pancreatic cancer. It has a poor response to conventional therapy and has an extremely poor 5-year survival rate. PDAC is driven by multiple oncogene mutations, with the highest mutation frequency being observed in KRAS. The KRAS protein, which binds to GTP, has phosphokinase activity, which further activates downstream effectors. KRAS mutation contributes to cancer cell proliferation, metabolic reprogramming, immune escape, and therapy resistance in PDAC, acting as a critical driver of the disease. Thus, KRAS mutation is positively associated with poorer prognosis in pancreatic cancer patients. This review focus on the KRAS mutation patterns in PDAC, and further emphases its role in signal transduction, metabolic reprogramming, therapy resistance and prognosis, hoping to provide KRAS target therapy strategies for PDAC.

引用

页数：16

共 160 条

[61] KrasG12D and Smad4/Dpc4 haploinsufficiency cooperate to induce mucinous cystic neoplasms and invasive adenocarcinoma of the pancreas [J].

Izeradjene, Kamel ;

Combs, Chelsea ;

Best, Melissa ;

Gopinathan, Aarthi ;

Wagner, Amary ;

Girady, William M. ;

Deng, Chu-Xia ;

Hruban, Ralph H. ;

Adsay, N. Volkan ;

Tuveson, David A. ;

Hingorani, Sunil R. .

CANCER CELL, 2007, 11 (03) :229-243

[62] FBW7 (F-box andWDRepeat Domain-Containing 7) Negatively Regulates Glucose Metabolism by Targeting the c-Myc/TXNIP (Thioredoxin-Binding Protein) Axis in Pancreatic Cancer [J].

Ji, Shunrong ;

Qin, Yi ;

Liang, Chen ;

Huang, Run ;

Shi, Si ;

Liu, Jiang ;

Jin, Kaizhou ;

Liang, Dingkong ;

Xu, Wenyan ;

Zhang, Bo ;

Liu, Liang ;

Liu, Chen ;

Xu, Jin ;

Ni, Quanxing ;

Chiao, Paul J. ;

Li, Min ;

Yu, Xianjun .

CLINICAL CANCER RESEARCH, 2016, 22 (15) :3950-3960

[63] Precise and efficient silencing of mutant KrasG12D by CRISPR-CasRx controls pancreatic cancer progression [J].

Jiang, Wang ;

Li, Hao ;

Liu, Xiyu ;

Zhang, Jianping ;

Zhang, Wuhu ;

Li, Tianjiao ;

Liu, Liang ;

Yu, Xianjun .

THERANOSTICS, 2020, 10 (25) :11507-11519

[64] Pancreatic stellate cells regulate branched-chain amino acid metabolism in pancreatic cancer [J].

Jiang, Wenna ;

Qiao, Lu ;

Han, Yawei ;

Zhang, Aimin ;

An, Haohua ;

Xiao, Jiawei ;

Ren, Li .

ANNALS OF TRANSLATIONAL MEDICINE, 2021, 9 (05)

[65] Lipid raft protein flotillin-1 is important for the interaction between SOS1 and H-Ras/K-Ras, leading to Ras activation [J].

Jin, Hao ;

Koh, Minsoo ;

Lim, Hyesol ;

Yong, Hae-Young ;

Kim, Eun-Sook ;

Kim, Sun Young ;

Kim, Kyoungmee ;

Jung, Joohee ;

Ryu, Won-Ji ;

Choi, Kang-Yell ;

Moon, Aree .

INTERNATIONAL JOURNAL OF CANCER, 2023, 152 (09) :1933-1946

[66] Mutant Kras- and p16-regulated NOX4 activation overcomes metabolic checkpoints in development of pancreatic ductal adenocarcinoma [J].

Ju, Huai-Qiang ;

Ying, Haoqiang ;

Tian, Tian ;

Ling, Jianhua ;

Fu, Jie ;

Lu, Yu ;

Wu, Min ;

Yang, Lifeng ;

Achreja, Abhinav ;

Chen, Gang ;

Zhuang, Zhuonan ;

Wang, Huamin ;

Nagrath, Deepak ;

Yao, Jun ;

Hung, Mien-Chie ;

DePinho, Ronald A. ;

Huang, Peng ;

Xu, Rui-Hua ;

Chiao, Paul J. .

NATURE COMMUNICATIONS, 2017, 8

[67] Irinotecan and vandetanib create synergies for treatment of pancreatic cancer patients with concomitant TP53 and KRAS mutations [J].

Kaushik, Aman Chandra ;

Wang, Yan-Jing ;

Wang, Xiangeng ;

Wei, Dong-Qing .

BRIEFINGS IN BIOINFORMATICS, 2021, 22 (03)

[68] Global Phosphoproteomics Reveal CDK Suppression as a Vulnerability to KRas Addiction in Pancreatic Cancer [J].

Kazi, Aslamuzzaman ;

Chen, Liwei ;

Xiang, Shengyan ;

Vangipurapu, Rajanikanth ;

Yang, Hua ;

Beato, Francisca ;

Fang, Bin ;

Williams, Terence M. ;

Husain, Kazim ;

Underwood, Patrick ;

Fleming, Jason B. ;

Malafa, Mokenge ;

Welsh, Eric A. ;

Koomen, John ;

Trevino, Jose ;

Sebti, Said M. .

CLINICAL CANCER RESEARCH, 2021, 27 (14) :4012-4024

[69] Efficacy of a Small-Molecule Inhibitor of KrasG12D in Immunocompetent Models of Pancreatic Cancer [J].

Kemp, Samantha B. ;

Cheng, Noah ;

Markosyan, Nune ;

Sor, Rina ;

Kim, Il-Kyu ;

Hallin, Jill ;

Shoush, Jason ;

Quinones, Liz ;

Brown, Natalie V. ;

Bassett, Jared B. ;

Joshi, Nikhil ;

Yuan, Salina ;

Smith, Molly ;

Vostrejs, William P. ;

Perez-Vale, Kia Z. ;

Kahn, Benjamin ;

Mo, Feiyan ;

Donahue, Timothy R. ;

Radu, Caius G. ;

Clendenin, Cynthia ;

Christensen, James G. ;

Vonderheide, Robert H. ;

Stanger, Ben Z. .

CANCER DISCOVERY, 2023, 13 (02) :298-311

[70] Yap/Taz promote the scavenging of extracellular nutrients through macropinocytosis [J].

King, Bryan ;

Araki, Jingwen ;

Palm, Wilhelm ;

Thompson, Craig B. .

GENES & DEVELOPMENT, 2020, 34 (19-20) :1345-1358

← 2 3 4 5 6 7 8 9 10 11 →